1. Birdwell KA, Decker B, Barbarino JM, Peterson JF, Stein CM, Sadee W, Wang D, Vinks AA, He Y, Swen JJ, Leeder JS, van Schaik R, Thummel KE, Klein TE, Caudle KE, MacPhee IA (2015) Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing. Clin Pharmacol Ther 98:19-24. http://doi.org/10.1002/cpt.113
2. Gueta I, Markovits N, Yarden-Bilavsky H, Raichlin E, Freimark D, Lavee J, Loebstein R, Peled Y (2018) High tacrolimus trough level variability is associated with rejections after heart transplant. Am J Transplant 18:2571-2578. http://doi.org/10.1111/ajt.15016
3. Sikma MA, Hunault CC, van de Graaf EA, Verhaar MC, Kesecioglu J, de Lange DW, Meulenbelt J (2017) High tacrolimus blood concentrations early after lung transplantation and the risk of kidney injury. Eur J Clin Pharmacol 73:573-580. http://doi.org/10.1007/s00228-017-2204-8
4. Zheng H, Zeevi A, Schuetz E, Lamba J, McCurry K, Griffith BP, Webber S, Ristich J, Dauber J, Iacono A, Grgurich W, Zaldonis D, McDade K, Zhang J, Burckart GJ (2004) Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism. J Clin Pharmacol 44:135-140. http://doi.org/10.1177/0091270003262108
5. Staatz CE, Tett SE (2004) Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 43:623-653. http://doi.org/10.2165/00003088-200443100-00001
6. Brunet M, van Gelder T, Åsberg A, Haufroid V, Hesselink DA, Langman L, Lemaitre F, Marquet P, Seger C, Shipkova M, Vinks A, Wallemacq P, Wieland E, Woillard JB, Barten MJ, Budde K, Colom H, Dieterlen MT, Elens L, Johnson-Davis KL, Kunicki PK, MacPhee I, Masuda S, Mathew BS, Millán O, Mizuno T, Moes DAR, Monchaud C, Noceti O, Pawinski T, Picard N, van Schaik R, Sommerer C, Vethe NT, de Winter B, Christians U, Bergan S (2019) Therapeutic drug monitoring of tacrolimus-personalized therapy: Second consensus report. Ther Drug Monit 41:261-307. http://doi.org/10.1097/FTD.0000000000000640
7. Hesselink DA, Bouamar R, Elens L, van Schaik RH, van Gelder T (2014) The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation. Clin Pharmacokinet 53:123-139. http://doi.org/10.1007/s40262-013-0120-3
8. Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, Nuessler AC, Neuhaus P, Klattig J, Eiselt R, Koch I, Zibat A, Brockmöller J, Halpert JR, Zanger UM, Wojnowski L (2001) The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11:773-779. http://doi.org/10.1097/00008571-200112000-00005
9. Yaowakulpatana K, Vadcharavivad S, Ingsathit A, Areepium N, Kantachuvesiri S, Phakdeekitcharoen B, Sukasem C, Sra-Ium S, Sumethkul V, Kitiyakara C (2016) Impact of CYP3A5 polymorphism on trough concentrations and outcomes of tacrolimus minimization during the early period after kidney transplantation. Eur J Clin Pharmacol 72:277-283. http://doi.org/10.1007/s00228-015-1990-0
10. Coller JK, Ramachandran J, John L, Tuke J, Wigg A, Doogue M (2019) The impact of liver transplant recipient and donor genetic variability on tacrolimus exposure and transplant outcome. Br J Clin Pharmacol 85:2170-2175. http://doi.org/10.1111/bcp.14034
11. Liu BY, Chen WQ, Chen ZG, Huang J, Liao ZK, Liu Q, Zheng Z, Song YH, Wang W, Hu SS (2019) The effects of CYP3A5 genetic polymorphisms on serum tacrolimus dose-adjusted concentrations and long-term prognosis in Chinese heart transplantation recipients. Eur J Drug Metab Pharmacokinet 44:771-776. http://doi.org/10.1007/s13318-019-00563-x
12. Monchaud C, de Winter BC, Knoop C, Estenne M, Reynaud-Gaubert M, Pison C, Stern M, Kessler R, Guillemain R, Marquet P, Rousseau A (2012) Population pharmacokinetic modelling and design of a bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation. Clin Pharmacokinet 51:175-186. http://doi.org/10.2165/11594760-000000000-00000
13. Miano TA, Flesch JD, Feng R, Forker CM, Brown M, Oyster M, Kalman L, Rushefski M, Cantu E, 3rd, Porteus M, Yang W, Localio AR, Diamond JM, Christie JD, Shashaty MGS (2020) Early tacrolimus concentrations after lung transplant are predicted by combined clinical and genetic factors and associated with acute kidney injury. Clin Pharmacol Ther 107:462-470. http://doi.org/10.1002/cpt.1629
14. Calabrese DR, Florez R, Dewey K, Hui C, Torgerson D, Chong T, Faust H, Rajalingam R, Hays SR, Golden JA, Kukreja J, Singer JP, Greenland JR (2018) Genotypes associated with tacrolimus pharmacokinetics impact clinical outcomes in lung transplant recipients. Clin Transplant 32:e13332. http://doi.org/10.1111/ctr.13332
15. Cai X, Song H, Jiao Z, Yang H, Zhu M, Wang C, Wei D, Shi L, Wu B, Chen J (2020) Population pharmacokinetics and dosing regimen optimization of tacrolimus in Chinese lung transplant recipients. Eur J Pharm Sci 152:105448. http://doi.org/10.1016/j.ejps.2020.105448
16. Zhang X, Xu J, Fan J, Zhang T, Li Y, Xie B, Zhang W, Lin S, Ye L, Liu Y, Jiang G (2017) Influence of IL-18 and IL-10 polymorphisms on tacrolimus elimination in Chinese lung transplant patients. Dis Markers 2017:7834035. http://doi.org/10.1155/2017/7834035
17. Khwaja A (2012) KDIGO clinical practice guidelines for acute kidney injury. Nephron Clinical Practice 120:c179-184. http://doi.org/10.1159/000339789
18. Tang HL, Xie HG, Yao Y, Hu YF (2011) Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 nonexpressers than expressers. Pharmacogenet Genomics 21:713-720. http://doi.org/10.1097/FPC.0b013e32834a48ca
19. Rojas L NI, Herrero MJ, Bosó V, Reig J, Poveda JL, Megías J, Bea S, Aliño SF (2015) Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: A systematic review and meta-analysis of observational studies. Pharmacogenomics 15:38-48. http://doi.org/10.1038/tpj.2014.38
20. Buendia JA, Bramuglia G, Staatz CE (2014) Effects of combinational CYP3A5 6986A>G polymorphism in graft liver and native intestine on the pharmacokinetics of tacrolimus in liver transplant patients: A meta-analysis. Ther Drug Monit 36:442-447. http://doi.org/10.1097/ftd.0000000000000032
21. Hendijani F, Azarpira N, Kaviani M (2018) Effect of CYP3A5*1 expression on tacrolimus required dose after liver transplantation: A systematic review and meta-analysis. Clin Transplant 32:e13306. http://doi.org/10.1111/ctr.13306
22. Andrews LM, Hesselink DA, van Schaik RHN, van Gelder T, de Fijter JW, Lloberas N, Elens L, Moes D, de Winter BCM (2019) A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients. Br J Clin Pharmacol 85:601-615. http://doi.org/10.1111/bcp.13838
23. Yamazaki H, Nakamoto M, Shimizu M, Murayama N, Niwa T (2010) Potential impact of cytochrome P450 3A5 in human liver on drug interactions with triazoles. Br J Clin Pharmacol 69:593-597. http://doi.org/10.1111/j.1365-2125.2010.03656.x
24. Vanhove T, Bouwsma H, Hilbrands L, Swen JJ, Spriet I, Annaert P, Vanaudenaerde B, Verleden G, Vos R, Kuypers DRJ (2017) Determinants of the magnitude of interaction between tacrolimus and voriconazole/posaconazole in solid organ recipients. Am J Transplant 17:2372-2380. http://doi.org/10.1111/ajt.14232
25. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383-391. http://doi.org/10.1038/86882
26. Dai Y, Hebert MF, Isoherranen N, Davis CL, Marsh C, Shen DD, Thummel KE (2006) Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab Dispos 34:836-847. http://doi.org/10.1124/dmd.105.008680
27. Woodahl EL, Hingorani SR, Wang J, Guthrie KA, McDonald GB, Batchelder A, Li M, Schoch HG, McCune JS (2008) Pharmacogenomic associations in ABCB1 and CYP3A5 with acute kidney injury and chronic kidney disease after myeloablative hematopoietic cell transplantation. Pharmacogenomics J 8:248-255. http://doi.org/10.1038/sj.tpj.6500472
28. Metalidis C, Lerut E, Naesens M, Kuypers DR (2011) Expression of CYP3A5 and P-glycoprotein in renal allografts with histological signs of calcineurin inhibitor nephrotoxicity. Transplantation 91:1098-1102. http://doi.org/10.1097/TP.0b013e3182177502
29. Bosó V, Herrero MJ, Bea S, Galiana M, Marrero P, Marqués MR, Hernández J, Sánchez-Plumed J, Poveda JL, Aliño SF (2013) Increased hospital stay and allograft dysfunction in renal transplant recipients with Cyp2c19 AA variant in SNP rs4244285. Drug Metab Dispos 41:480-487. http://doi.org/10.1124/dmd.112.047977
30. Flahault A, Anglicheau D, Loriot MA, Thervet E, Pallet N (2017) Clinical impact of the CYP3A5 6986A>G allelic variant on kidney transplantation outcomes. Pharmacogenomics 18:165-173. http://doi.org/10.2217/pgs-2016-0146
31. Woillard JB, Gatault P, Picard N, Arnion H, Anglicheau D, Marquet P (2018) A donor and recipient candidate gene association study of allograft loss in renal transplant recipients receiving a tacrolimus-based regimen. Am J Transplant 18:2905-2913. http://doi.org/10.1111/ajt.14894
32. Khan AR, Raza A, Firasat S, Abid A (2020) CYP3A5 gene polymorphisms and their impact on dosage and trough concentration of tacrolimus among kidney transplant patients: A systematic review and meta-analysis. Pharmacogenomics J 20:553-562. http://doi.org/10.1038/s41397-019-0144-7
33. van Gelder T, Meziyerh S, Swen JJ, de Vries APJ, Moes D (2020) The clinical impact of the C0/D ratio and the CYP3A5 genotype on outcome in tacrolimus treated kidney transplant recipients. Front Pharmacol 11:1142. http://doi.org/10.3389/fphar.2020.01142
34. Jouve T, Fonrose X, Noble J, Janbon B, Fiard G, Malvezzi P, Stanke-Labesque F, Rostaing L (2020) The TOMATO study (Tacrolimus Metabolization in Kidney Transplantation): Impact of the concentration-dose ratio on death-censored graft survival. Transplantation 104:1263-1271. http://doi.org/10.1097/tp.0000000000002920